Review Reports

Round 1

Reviewer 1 Report

Authors present data on CDK1-related ceRNA network analysis from TCGA suggesting potential diagnostic biomarkers or therapeutic targets for lung adenocarcinoma treatment  from pathways related to LINC00460/LINC00525–hsa-mir-338–FAM111/ZWINT.

Methods and results are clear.

Language needs minor check and spelling check.

Some specific comments for section are listed below:

--Introduction needs to be improved, by adding more info on actual standard of care for lung cancer.

--Figure 1 shows descriptive data on CDK1 in TCGA. Is it possibile to summarize these data for better clarity in a summary table?

Some new analysis may help in improve the quality of data:

- Is it possible to add some data on correlation with EMT features?

- Data on immune infiltration are very interesting and promising. Can authors correlate these data with PD-L1 or immune scores available from literature for NSCLC? (see PMID: 32068166).

- Mutations of  FAM111B and ZWINT are presented. Is it possible to analyze the  co-mutations of these genes with other important genes related to LUAD  carcinogenesis (e.g. TP53, EGFR, KRAS)?

-- Discussion can also be improved by introducing some data on epithelial to emsenchymal transition as mechanism of resistance to theraphy in LUAD.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The paper offers an interesting approach resulting in the construction of an axis that should be able to detect novel therapeutic targets.

Major issue: There is not enough clinical understanding of LUAD. LUAD is presented and discussed as a homogenous cancer. In reality prognosis of the disease is varying extremely depending on driver mutation or immunogenicity scored by PD-L1-IHC. The minimum approach to publish in a high-ranked journal would be to deliver full data on mutational status, PD-L1-expression, TMB plus clinical characteristics like smoking status.

 

minor: the role of EMT in the resistance of EGFR-mut tumours really play a minor role. Consider involving a clinician specialized in the treatment of lung cancer

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Authors improved manuscript.

I would just suggest to remove oxalipatin from drugs cited in intro since it is not used worldwide for NSCLC.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Thank you very much for addressing my comments. Sorry to see that only a few driver mutations are included. 

Comment 2 was maybe misunderstood as it is not addressed in the answer. It was about the role of EMT in acquired EGFR-TKI-resistance

Author Response

Please see the attachment.

Author Response File: Author Response.pdf